Royal Bank Of Canada Clearside Biomedical, Inc. Transaction History

Royal Bank Of Canada

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.08 - $1.58 $613 - $897	568 New	568 $0
Q4 2023 Feb 14, 2024	SELL	$0.68 - $1.18 $30,464 - $52,865	-44,801 Reduced 99.5%	225 $0
Q3 2023 Nov 14, 2023	BUY	$0.82 - $1.27 $36,658 - $56,776	44,706 Added 13970.63%	45,026 $39,000
Q2 2023 Aug 14, 2023	BUY	$0.97 - $1.48 $300 - $458	310 Added 3100.0%	320 $0
Q1 2023 May 15, 2023	SELL	$0.93 - $1.66 $0 - $1	-1 Reduced 9.09%	10 $0
Q4 2022 Feb 14, 2023	SELL	$1.0 - $1.5 $251 - $376	-251 Reduced 95.8%	11 $0
Q3 2022 Nov 14, 2022	BUY	$1.08 - $1.83 $282 - $479	262 New	262 $0
Q2 2022 Aug 15, 2022	SELL	$1.3 - $2.49 $494 - $946	-380 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.35 - $2.88 $861 - $1,837	-638 Reduced 62.67%	380 $1,000
Q4 2021 Feb 14, 2022	BUY	$2.72 - $5.72 $2,768 - $5,822	1,018 New	1,018 $3,000

12.2M

54.7K

50.7K

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $62M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.